GORDANA VUNJAK-NOVAKOVIC

Gordana Vunjak-Novakovic stands as a pivotal figure in both the scientific community and the venture capital landscape, particularly within the biomedical sector. As a distinguished Venture Partner at Catalio Capital, she brings an unparalleled depth of scientific insight and strategic vision to the firm's investment decisions. Catalio Capital is renowned for its focus on transformative biomedical technologies, and Dr. Vunjak-Novakovic's expertise is instrumental in identifying and nurturing the next generation of life science innovators.

Her investment focus areas at Catalio Capital are deeply rooted in her pioneering academic and research career. She targets groundbreaking advancements in tissue engineering, regenerative medicine, cell therapies, biomaterials, and other cutting-edge biotechnologies. Dr. Vunjak-Novakovic plays a crucial role in evaluating the scientific merit and commercial potential of early-stage and growth-stage companies, ensuring that Catalio Capital invests in solutions with the highest probability of making a significant impact on human health.

Dr. Vunjak-Novakovic's career background is nothing short of illustrious. She is a University Professor at Columbia University, holding appointments in Biomedical Engineering and the College of Physicians and Surgeons. Widely recognized as a pioneer in the field of tissue engineering, her research has led to significant breakthroughs in creating functional tissues for repair and regeneration. Her work has been extensively published in leading scientific journals, and she holds numerous patents that have formed the basis for several successful biotech startups she has co-founded.

Her contributions to science have earned her membership in prestigious national academies, including the National Academy of Engineering, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences. These accolades underscore her profound impact on biomedical science and innovation. Her unique position at the intersection of academia and venture capital allows her to bridge the gap between fundamental scientific discovery and its translation into viable commercial products and therapies.

While specific individual investments are often proprietary, Dr. Vunjak-Novakovic's involvement ensures that Catalio Capital's portfolio companies benefit from rigorous scientific due diligence and strategic guidance from a world-leading expert. Her ability to discern promising technologies and guide their development is invaluable, positioning Catalio Capital at the forefront of biomedical venture capital and driving advancements that promise to revolutionize healthcare.